| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.2 | 1.6 |
| Net income | -28.1 | -17.9 |
| EPS (diluted, $ a share) | $-1.74 | $-1.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +42.6% |
|---|
10-Q filed with the SEC, NASDAQ: ADRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ADARx Pharmaceuticals, Inc.: key numbers
- Share price
- $14.00Close, Nov 16
- Market cap
- $1.56B
- Shares outstanding
- 111.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ADARx Pharmaceuticals, Inc.
All →ADARx Pharmaceuticals Financial Results
ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.
“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
ADARx Pharmaceuticals Insider Erez Chimovits Buys $1.05M of Stock
Erez Chimovits bought 61,516 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $1.05M in total on Sep 28, 2026. Shares held after the trade: 9,292,025 (+0.7%).
- Value
- $1.05M
- Shares
- 61,516
- Price
- $17.00
- Holding change
- +0.7%
- Trade date
- Sep 28, 2026
ADARx Pharmaceuticals Insider Carl L. Gordon Buys $16.1M of Stock
Carl L. Gordon bought 950,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $16.1M in total on Sep 28, 2026. Shares held after the trade: 9,292,025 (+0.7%).
- Value
- $16.1M
- Shares
- 950,000
- Average price
- $17.00
- Holding change
- +0.7%
- Trade date
- Sep 28, 2026
ADARx Pharmaceuticals Insider Orbimed Advisors LLC Buys $16.1M of Stock
Orbimed Advisors LLC bought 950,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $16.1M in total on Sep 28, 2026. Shares held after the trade: 9,292,025 (+0.7%).
- Value
- $16.1M
- Shares
- 950,000
- Average price
- $17.00
- Holding change
- +0.7%
- Trade date
- Sep 28, 2026
ADARx Pharmaceuticals Director Simeon George Buys $27.2M of Stock
Simeon George, Director, bought 1,600,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $27.2M in total on Sep 28, 2026. Shares held after the trade: 592,593.
- Value
- $27.2M
- Shares
- 1,600,000
- Average price
- $17.00
- Role
- Director
- Trade date
- Sep 28, 2026
ADARx Pharmaceuticals 10% Owner Sr One Capital Management LLC Buys $27.2M of Stock
Sr One Capital Management LLC, 10% Owner, bought 1,600,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $27.2M in total on Sep 28, 2026. Shares held after the trade: 592,593.
- Value
- $27.2M
- Shares
- 1,600,000
- Average price
- $17.00
- Role
- 10% Owner
- Trade date
- Sep 28, 2026